Sang Hoon Ahn
Welcome,         Profile    Billing    Logout  
 31 Trials 
22 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Do Young
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
NCT05808335: A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

Recruiting
2a
32
RoW
Standard of care
ImmuneMed, Inc.
Chronic Hepatitis B
03/24
12/24
IDADOX, NCT06114082: TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

Recruiting
2
128
RoW
IDA-TACE, Conventional TACE using idarubicin chemoemulsion, DOX-TACE, Conventional TACE using doxorubicin chemoemulsion
Seoul National University Hospital, Guerbet
Hepatocellular Carcinoma, Liver Cancer
12/25
06/26
MIV-818-101, NCT03781934 / 2018-000995-14: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations

Active, not recruiting
1/2
53
Europe, RoW
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Medivir
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
01/25
06/25
Kim, Seung Up
ALSummit, NCT04745299: Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS

Active, not recruiting
3
115
RoW
Lenzumestrocel, Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Riluzole, Rilutek, Placebo Comparator, Normal Saline Inj.
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
12/24
05/26
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting
3
226
NA
LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
Green Cross Wellbeing
Chronic Liver Disease
12/25
12/25
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Active, not recruiting
3
158
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Recruiting
2
49
RoW
LAENNEC (Human Placenta Hydrolysate), normal saline
Green Cross Wellbeing
Chronic Liver Disease
03/23
06/23
PROCEADE PanTumor, NCT06710132: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors

Recruiting
1/2
250
Japan, US, RoW
M9140, Precemtabart tocentecan
EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
01/29
01/29
KEYNOTE-G08, NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US, RoW
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
11/25
04/27
NCT06676423: Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Completed
1
8
RoW
Lenzumestrocel, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell, Riluzole, Rilutek
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
11/23
11/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors

Recruiting
1
400
Europe, US, RoW
KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib
Pierre Fabre Medicament
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
11/28
03/29
NCT04801095: A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Recruiting
1
100
RoW
WM-S1-030
Wellmarker Bio, Covance
Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Cholangiocarcinoma, Head and Neck Cancer
08/25
08/25
NCT04122833: Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Recruiting
N/A
80
RoW
Next generation sequencing
Konkuk University Medical Center, Roche Diagnostics, Foundation Medicine
Adenocarcinoma of Lung, EGFR Activating Mutation
09/23
12/24
Han, Kwang-Hyub
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
Park, Jun Yong
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT06093321: A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement

Recruiting
N/A
55
RoW
SYB PDO Thread, MINT lift®
Samyang Biopharmaceuticals Corporation
Nasolabial Folds
05/24
02/25
Park, Hana
No trials found
Chon, Young Eun
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Do Young
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
NCT05808335: A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

Recruiting
2a
32
RoW
Standard of care
ImmuneMed, Inc.
Chronic Hepatitis B
03/24
12/24
IDADOX, NCT06114082: TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

Recruiting
2
128
RoW
IDA-TACE, Conventional TACE using idarubicin chemoemulsion, DOX-TACE, Conventional TACE using doxorubicin chemoemulsion
Seoul National University Hospital, Guerbet
Hepatocellular Carcinoma, Liver Cancer
12/25
06/26
MIV-818-101, NCT03781934 / 2018-000995-14: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations

Active, not recruiting
1/2
53
Europe, RoW
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Medivir
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
01/25
06/25
Kim, Seung Up
ALSummit, NCT04745299: Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS

Active, not recruiting
3
115
RoW
Lenzumestrocel, Neuronata-R inj, Autologous Bone Marrow derived Mesenchymal Stem Cell, Riluzole, Rilutek, Placebo Comparator, Normal Saline Inj.
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
12/24
05/26
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting
3
226
NA
LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
Green Cross Wellbeing
Chronic Liver Disease
12/25
12/25
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Active, not recruiting
3
158
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Recruiting
2
49
RoW
LAENNEC (Human Placenta Hydrolysate), normal saline
Green Cross Wellbeing
Chronic Liver Disease
03/23
06/23
PROCEADE PanTumor, NCT06710132: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors

Recruiting
1/2
250
Japan, US, RoW
M9140, Precemtabart tocentecan
EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
01/29
01/29
KEYNOTE-G08, NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US, RoW
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), ENHERTU®, pembrolizumab, KEYTRUDA®
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
11/25
04/27
NCT06676423: Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Completed
1
8
RoW
Lenzumestrocel, Neuronata-R, Autologous Bone Marrow derived Mesenchymal Stem cell, Riluzole, Rilutek
Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
11/23
11/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors

Recruiting
1
400
Europe, US, RoW
KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib
Pierre Fabre Medicament
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
11/28
03/29
NCT04801095: A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Recruiting
1
100
RoW
WM-S1-030
Wellmarker Bio, Covance
Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Cholangiocarcinoma, Head and Neck Cancer
08/25
08/25
NCT04122833: Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Recruiting
N/A
80
RoW
Next generation sequencing
Konkuk University Medical Center, Roche Diagnostics, Foundation Medicine
Adenocarcinoma of Lung, EGFR Activating Mutation
09/23
12/24
Han, Kwang-Hyub
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
Park, Jun Yong
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT06093321: A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement

Recruiting
N/A
55
RoW
SYB PDO Thread, MINT lift®
Samyang Biopharmaceuticals Corporation
Nasolabial Folds
05/24
02/25
Park, Hana
No trials found
Chon, Young Eun
No trials found

Download Options